SV Life Sciences (SVLS), a life sciences venture capital firm with offices in Boston, London and San Francisco, has appointed Joshua Resnick as Partner. Based in Boston, Resnick joins SVLS’ biotech investment team which partners with experienced entrepreneurs and accomplished management teams.
“Resnick brings deep investment leadership experience to SV Life Sciences that immediately expands the biotech capabilities of our firm,” said Mike Ross, SVLS Managing Partner and head of the U.S. biotechnology team.
Resnick joined as President and Managing Partner from MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co. Prior to this, he was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, he was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. He is a board director of miRagen Therapeutics, Alector, RaNA Therapeutics, Spero Therapeutics and Visterra.
SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. Now the company advises or manages five funds with capital commitments of approximately USD1.9 billion which primarily invest amounts of between USD1 million and USD40 million in North America and Europe.